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I
 
n our first review on chemokines (1), we suggested that
blockade of the IL-8 receptor or inhibition of IL-8 gene
expression could be a new principle for designing antiin-
flammatory agents. The unexpected growth of the chemo-
kine  family and consequent redundancy of the system
eventually made it clear that acting at the level of chemo-
kine gene expression was rather hopeless, but the idea of
influencing inflammation with chemokine receptor antag-
onists has remained valid and inhibitors were recently put
to the test. A new literature, including several articles in
this issue of 
 
The Journal of Experimental Medicine
 
, indicate
that the idea was worth trying.
 
How to Make a Chemokine Receptor Antagonist.
 
By scan-
ning mutagenesis (2) and selective deletion or substitution
of NH
 
2
 
-terminal residues (3, 4) it was shown that the Glu-
Leu-Arg (ELR) motif preceding the first cysteine is essen-
tial for IL-8 activity. The ELR motif is conserved in all
CXC chemokines that act on neutrophils (ELR chemo-
kines) and is recognized by both IL-8 receptors, CXCR1
and CXCR2. It contributes to high-affinity binding and is
the receptor triggering part of the molecule (5). The ELR
motif alone, however, is not sufficient since linear and cy-
clic ELR-containing oligopeptides do not bind to the IL-8
receptors nor stimulate neutrophils (4). ELR chemokines
have additional, selective binding sites, and it was not possi-
ble to confer activity on neutrophils to IP10 or monocyte
chemoattractant protein (MCP)-1 by introducing the ELR
motif at the NH
 
2
 
 terminus (4). The three-dimensional nu-
clear magnetic resonance structure of IL-8 (6) shows that
the conformationally disordered NH
 
2
 
-terminal domain is
anchored by the disulfide bonds to the well-ordered core
of the protein. It is believed that interactions with domains
of the core determine receptor selectivity and facilitate the
access of the ELR motif to the receptor triggering site.
The first chemokine antagonist was obtained by trunca-
tion of IL-8. The analogue with an NH
 
2
 
-terminal arginine
followed by the first cysteine, (R)IL-8, is inactive on neu-
trophils, but still has considerable receptor affinity and effi-
ciently competes for binding with IL-8 and other ELR
chemokines inhibiting their biological activities. Other an-
tagonists were obtained by substitution within the ELR
motif, and one of the most potent is (AAR)IL-8 (7). An-
tagonists are also generated by truncation of other ELR
chemokines, which have high affinity for CXCR2, but
only low affinity for CXCR1. Although (R)IL-8 blocks
equally well, CXCR1 and CXCR2, the corresponding an-
alogues of GRO
 
a
 
 and platelet factor (PF) 4, (R) growth
regulated protein (GRO)
 
a
 
 and (R)PF4, block only CXCR2
(8). These observations indicate that receptor selectivity of
ELR chemokines is determined by binding domains be-
yond the NH
 
2
 
-terminal region. It is interesting, however,
that the arginine preceding the first cysteine is an absolute
requirement for recognition by both IL-8 receptors and
that the Arg-Cys
 
1
 
 arrangement also occurs in the chemo-
kines that act via CXCR3 (IP10 and Mig) and CXCR4
(stromal cell–derived factor [SDF]-1).
NH
 
2
 
 terminally truncated CC chemokines are also po-
tent antagonists. MCP-1 derivatives obtained by deletion
of eight or nine NH
 
2
 
-terminal residues, MCP-1(9-76) and
MCP-1(10-76) block CCR2 and prevent the responses
elicited by MCP-1, MCP-2, and MCP-3, but not by
RANTES, macrophage inflammatory protein (MIP)-1
 
a
 
,
or MIP-1
 
b
 
 (9). By contrast the corresponding truncation
analogues of RANTES, RANTES(9-68), and MCP-3,
MCP-3(10-76), block more than one CC chemokine re-
ceptor and inhibit the responses induced by MCP-1,
MCP-3, and RANTES (10). The loss of selectivity suggests
that determinants within the NH
 
2
 
-terminal domain are im-
portant for receptor recognition by these chemokines. In
addition, antagonists were obtained by NH
 
2
 
-terminal ex-
tension of MCP-3 with Arg-Glu-Phe (11) or RANTES
with a methionine (12), and by chemical modification of
the NH
 
2
 
 terminus of RANTES (13).
 
A Lot of Impetus from HIV.
 
The recent discovery that
chemokine receptors, together with CD4, act as recogni-
tion sites for HIV infection and that some chemokines have
HIV-suppressive activity (14) boosted the search for thera-
peutic strategies targeting chemokine receptors. A basic
question had to be answered, however, before going to
work. Is the inhibition of viral entry dependent on chemo-
kine activity and/or chemokine receptor signaling, or are
the chemokines simply competing for the virus binding
site? It was shown that the entry of M-tropic strains is pre-
vented by RANTES antagonists (13, 15). This was an im-
portant observation since the use of natural chemokines to
block infection was considered potentially dangerous be-
cause of side effects due to leukocyte activation.
In this issue, Wu et al. (16) show that CCR5 can be
blocked by mAbs. Although chemokines and viral gp120
compete for the same receptor, their binding sites are partly
different. To map the sites, Wu et al. (16) generated a panel
of mAbs and studied their effects on the interaction of
M-tropic HIV-1 strains and chemokines with chimeric re-
ceptors consisting of different portions of CCR5 and CCR2b.
An antibody, 2D7, recognizing the second extracellular
loop of CCR5 blocks the binding and the biological activ-
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ity of all three chemokine ligands, RANTES, MIP-1
 
a
 
, and
MIP-1
 
b
 
, as well as infection by M-tropic and dual-tropic
HIV-1 strains indicating that this domain is shared by the
chemokines and gp120. By contrast, antibodies binding to
the NH
 
2
 
-terminal region of CCR5 block infection, but
have no effect on chemokine activity. Wu et al. consider
the second extracellular loop as the most promising target
for blocking agents because this domain appears to be es-
sential for chemokine as well as virus binding.
 
Handy Inhibitors Coming.
 
Chemokines and chemokine
mutants with antagonist properties are far from being ideal
drugs. As proteins, they pose galenical problems and are
unlikely to be orally active. This issue of 
 
The Journal of Ex-
perimental Medicine
 
 brings news from Europe, Japan, and the
United States indicating that HIV–coreceptor interactions
can be inhibited with chemokine-unrelated, low-molecu-
lar weight compounds. Three compounds are presented
that were previously known for their inhibitory effects on
HIV replication. They block the entry of T-, but not M-tropic
strains by interacting with CXCR4. In cells expressing
only CXCR4 and CD4, inhibition of dual-tropic strains is
also observed.
Schols et al. (17) describe the effect of AMD3100, which
belongs to a class of heterocyclic compounds called bicy-
clams. AMD3100 inhibits the entry of T-tropic viruses,
competes for the binding of an mAb that is specific for
CXCR4, and blocks SDF-1 dependent Ca
 
2
 
1
 
 mobilization
and chemotaxis in receptor-expressing cells. Together with
the lack of effects on CCR5-, CCR1-, and CCR2b-depen-
dent activities, these data demonstrate that AMD3100 is se-
lective for CXCR4. AMD3100 appears to be effective in
vivo and, as suggested by in vitro data, to be more potent as
inhibitor of HIV entry than of SDF-1–mediated functions.
This dissociation may be important because blockade of
SDF-1 activity could be dangerous, as suggested by the de-
fects observed in mice lacking the SDF-1 gene (18).
Murakami et al. (19) present an 18-residue peptide, T22,
an amusing derivative of polyphemusin II, that specifically
inhibits Env-dependent fusion and infection by T-tropic
strains of cells transfected with CXCR4 and CD4, as well
as PBMC. Since T22 also inhibits Ca
 
2
 
1
 
 mobilization in-
duced by SDF-1, the antiviral activity is likely to depend
on competition for coreceptor binding by the virus. As for
the bicyclam, the in vitro data suggest that significant anti-
viral activity is obtained at concentrations of T22 that only
partially block the responses to SDF-1. More thorough
studies, however, must be performed to clarify this point.
Interestingly, Murakami et al. have compared T22 with an
inactive analogue of similar size and physicochemical prop-
erties. This control strengthens the evidence for the selec-
tive mode of action of T22.
Doranz et al. (20) describe similar effects of a highly cat-
ionic oligopeptide containing nine arginines, ALX40-4C,
that inhibits Env-dependent fusion and entry of T-tropic
HIV strains by interacting with CXCR4. ALX40-4C also
prevents Ca
 
2
 
1
 
 mobilization in response to SDF-1 and the
binding of Hoxie’s mAb, 12G5, which is known to recog-
nize the first and second extracellular loop of CXCR4 and
to inhibit virus entry. The interaction between ALX40-4C
and the receptor loops is likely to depend on charge since
the loops contain several anionic residues. Such an interac-
tion cannot occur with CCR5, explaining why infection
by M-tropic viruses is not affected by ALX40-4C. The au-
thors point out that their antiviral compound also inhibits
infection by type 1 herpes simplex suggesting that interac-
tions with other receptor proteins may occur.
It is somewhat surprising that all three low molecular
weight coreceptor inhibitors described in this issue interact
with CXCR4 and not with other coreceptors. Since the
compounds were all known for their antiviral properties, it
is possible that the screening criteria adopted for their selec-
tion were biased in favor of inhibition of CXCR4-depen-
dent viruses. On the other hand, inhibitors of CXCR4
may simply be easier to find. The present finding of three
structurally different compounds with similar biological ef-
fects indicates that modeling of the interactions with the
receptor could help to design compounds that bind to
CCR5, or preferably to more than one coreceptor.
 
The Next Steps.
 
The evidence for effective chemokine
receptor blockade by small compounds, some of which
have a good chance to be bioavailable after oral application,
is a promising starting point. The current developments
should not be restricted to antiviral therapy, since chemo-
kine antagonists can be potentially useful as antiinflamma-
tory, antiallergic, and immunoregulatory agents. A paper
that appeared in the July 7th issue of 
 
The Journal of Experi-
mental Medicine
 
 demonstrates that a selective antagonist of
CCR2, the MCP receptor, has antinflammatory properties
in vivo. Gong et al. (21) show that repeated injections of a
truncated analogue of MCP-1, MCP-1(9-76), prevents the
chronic inflammatory arthritis that spontaneously develops
in MRL-
 
lpr
 
 mice. In contrast, controls that were treated
with wild-type MCP-1 had more marked arthritis symp-
toms. Given the selectivity of the antagonist the results of
this study highlight the validity of chemokine receptor
blockade as antiinflammatory principle.
Although the present papers clearly show that chemo-
kine receptor inhibitors are promising as potential drugs,
considerable work still has to be done to gain information
about specificities and the mode of action of the inhibitors.
It is also important to define shared and selective recogni-
tion sites for chemokines and the V3 loop of gp120, and to
determine their affinities and their binding kinetics. With
this background it will be possible to optimize low molec-
ular weight compounds as inhibitors of the binding of
gp120 or chemokines, and to design antagonists that act on
multiple receptors.
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